These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Increasing the Antimicrobial Activity of Nisin-Based Lantibiotics against Gram-Negative Pathogens. Li Q; Montalban-Lopez M; Kuipers OP Appl Environ Microbiol; 2018 Jun; 84(12):. PubMed ID: 29625984 [TBL] [Abstract][Full Text] [Related]
5. Cesin, a short natural variant of nisin, displays potent antimicrobial activity against major pathogens despite lacking two C-terminal macrocycles. Guo L; Wambui J; Wang C; Muchaamba F; Fernandez-Cantos MV; Broos J; Tasara T; Kuipers OP; Stephan R Microbiol Spectr; 2023 Sep; 11(5):e0531922. PubMed ID: 37754751 [TBL] [Abstract][Full Text] [Related]
6. Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. Field D; Quigley L; O'Connor PM; Rea MC; Daly K; Cotter PD; Hill C; Ross RP Microb Biotechnol; 2010 Jul; 3(4):473-86. PubMed ID: 21255345 [TBL] [Abstract][Full Text] [Related]
7. Bioengineering of the model lantibiotic nisin. Field D; Cotter PD; Ross RP; Hill C Bioengineered; 2015; 6(4):187-92. PubMed ID: 25970137 [TBL] [Abstract][Full Text] [Related]
8. Intensive mutagenesis of the nisin hinge leads to the rational design of enhanced derivatives. Healy B; Field D; O'Connor PM; Hill C; Cotter PD; Ross RP PLoS One; 2013; 8(11):e79563. PubMed ID: 24244524 [TBL] [Abstract][Full Text] [Related]
9. Systematic characterization of position one variants within the lantibiotic nisin. Lagedroste M; Reiners J; Smits SHJ; Schmitt L Sci Rep; 2019 Jan; 9(1):935. PubMed ID: 30700815 [TBL] [Abstract][Full Text] [Related]
11. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. Piper C; Draper LA; Cotter PD; Ross RP; Hill C J Antimicrob Chemother; 2009 Sep; 64(3):546-51. PubMed ID: 19561147 [TBL] [Abstract][Full Text] [Related]
15. Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Geitani R; Ayoub Moubareck C; Touqui L; Karam Sarkis D BMC Microbiol; 2019 Mar; 19(1):54. PubMed ID: 30849936 [TBL] [Abstract][Full Text] [Related]
16. Bioengineering nisin to overcome the nisin resistance protein. Field D; Blake T; Mathur H; O' Connor PM; Cotter PD; Paul Ross R; Hill C Mol Microbiol; 2019 Mar; 111(3):717-731. PubMed ID: 30537404 [TBL] [Abstract][Full Text] [Related]
17. Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery. Escano J; Ravichandran A; Salamat B; Smith L Appl Environ Microbiol; 2017 Jul; 83(14):. PubMed ID: 28500042 [TBL] [Abstract][Full Text] [Related]
18. Bypassing lantibiotic resistance by an effective nisin derivative. Zaschke-Kriesche J; Behrmann LV; Reiners J; Lagedroste M; Gröner Y; Kalscheuer R; Smits SHJ Bioorg Med Chem; 2019 Aug; 27(15):3454-3462. PubMed ID: 31253534 [TBL] [Abstract][Full Text] [Related]
19. Nisin- and Ripcin-Derived Hybrid Lanthipeptides Display Selective Antimicrobial Activity against Zhao X; Kuipers OP ACS Synth Biol; 2021 Jul; 10(7):1703-1714. PubMed ID: 34156232 [TBL] [Abstract][Full Text] [Related]
20. Insights into the mode of action of the two-peptide lantibiotic haloduracin. Oman TJ; van der Donk WA ACS Chem Biol; 2009 Oct; 4(10):865-74. PubMed ID: 19678697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]